Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial

Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial

Abstract Objectives The study objective is to quantify the effectiveness of ivermectin (subcutaneous/oral IVM) in the presence or absence of zinc (Zn) for clinical and radiological improvement in coronavirus disease 2019 (COVID-19) patients with moderate severity. Trial design This quadruple-blinded...

Full description

Bibliographic Details
Main Authors: Shoaib Ashraf, Sohaib Ashraf, Iqra Farooq, Sidra Ashraf, Moneeb Ashraf, Muhammad Ahmad Imran, Larab Kalsoom, Rutaba Akmal, Muhammad Ghufran, Sundas Rafique, Muhammad Kiwan Akram, Zaigham Habib, Uzma Nasim Siddiqui, Ammara Ahmad, Shahroze Arshad, Muhammad Abdul Rehman Virk, Mehak Gul, Abeer bin Awais, Muhammad Hassan, Syed Sami Hussain Sherazi, Zartasha Safdar, Isra Munir, Hamna Khalid, Khalid Munir, Nighat Majeed, Yaser Masuod Alahmadi, Ayesha Humayun, Qazi Abdul Saboor, Ali Ahmad, Muhammad Ashraf, Mateen Izhar, DOCTORS LOUNGE Consortium
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Trials
Subjects:
Ivermectin
Zinc
Subcutaneous Ivermectin
Pakistan
COVID-19
Randomised controlled trial
Online Access:https://doi.org/10.1186/s13063-021-05487-z

Internet

https://doi.org/10.1186/s13063-021-05487-z

Similar Items